ROVI participates in the manufacture of the active substance of Moderna’s COVID-19 vaccine

Investment in a new production line at ROVI's Granada facility, which will lead to greater vertical integration in the vaccine production process


Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), a pan-European pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced that they will strengthen their collaboration for the manufacture of the active substance of the COVID-19 Vaccine Moderna. To this end, further industrial investment will be made in the ROVI Group’s facility in Granada (Spain).

This investment consists of the installation of a new line supporting production phases of the active substance of the mRNA vaccine, which are prior and additional to the compounding and fill-finish of the vaccine. This line will have a production capacity equivalent to more than 100 million doses per year and is expected to begin to supply markets outside the United States in the third quarter of 2021.

With this addition, ROVI will extend the activities it performs in the manufacturing process of the COVID-19 Vaccine Moderna: it will take part in the manufacture of the active substance, as well as the compounding, filling and final packaging before the vaccine is distributed for administration to patients.

“We are delighted at our collaboration with Moderna, whose vaccine against COVID-19 is one of the best- positioned in the race to solve this health crisis. We are hugely excited that ROVI is taking a further step forward and taking part in the manufacture of the vaccine’s active substance, since greater integration in the production process will allow us to support Moderna in its large-scale distribution more broadly. We are thrilled at the chance to increase our contribution to solving this pandemic that is affecting everyone. Our proven experience and capacities as a contract manufacturer of injectables with high technological value has enabled us to strengthen our present agreement with Moderna and this will help to reinforce our manufacturing area, probably providing us with a significant growth opportunity in this area. I would also like to thank the Ministry of Health and the Spanish Medicines Agency for making themselves available to us and providing their support during this entire process. This has been of vital importance.” Juan López-Belmonte Encina, ROVI’s Chief Executive Officer.

No votes yet
 
Related
Sustained-release drug delivery is a field where significant progress is being made that increases the efficacy of the medicines, improves...
3 min
24/11/2022
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION (COMISIÓN NACIONAL DEL MERCADO DE VALORES) Madrid, 23 November 2022 In...
1 min
23/11/2022
ROVI reports operating revenue growth of 24% and EBITDA growth of 25% • Operating revenue increased by 24% to 575.5 million euros driven...
3 min
04/11/2022